by Amrat Khorana | Sep 2, 2026 | News
Neurocrine Biosciences, the company that now markets VYKAT® XR (diazoxide choline) following its acquisition of Soleno Therapeutics, has published an open letter to the PWS community. The letter provides an update on the company’s plans for ongoing safety monitoring,...
by Farisha Colbourne | Aug 13, 2026 | News
IPWSO, PWSA | USA and the Foundation for Prader-Willi Research (FPWR) have jointly published a new statement for healthcare professionals, families, and caregivers regarding VYKAT XR (diazoxide choline), which is currently approved by the US Food and Drug...
by Farisha Colbourne | Jun 5, 2026 | News
We are delighted to announce the appointment of Amrat Khorana as our new Chief Executive Officer from 1 June 2026. A biomedical scientist by background, Amrat brings leadership experience across healthcare, education, regulation and the charity sector. Most recently,...
by Farisha Colbourne | May 29, 2026 | News
Many people in the PWS community have been following the development of new treatments for hyperphagia. Here is a summary of recent updates from Soleno Therapeutics and Aardvark Therapeutics, together with IPWSO’s comments. Soleno Therapeutics and...
by Nora McNairney | Feb 17, 2026 | News
Opportunities to attend the 17th African Society of Paediatric and Adolescent Endocrinology (ASPAE) Congress from 15-18 July 2026, Dakar, Senegal. In order to share knowledge about Prader-Willi syndrome (PWS) around the world, IPWSO is delighted to offer a limited...
by Farisha Colbourne | Jan 28, 2026 | News
We wish to share that Margaret Walker, our current CEO, will be stepping down from her role as Chief Executive Officer at IPWSO. The Trustees would like to thank Margaret for her contribution over the past year and express their sincere gratitude for the commitment,...
